Clinical Trial Search Results
Impact of Familial Hypercholesterolemia genetic testing on high-risk cardiovascular disease patient outcomes
This study is currently enrolling.
You are being invited to take part in a research study conducted by the AdventHealth Orlando in collaboration with Helix OpCo, LLC (“Helix”), a genetics company that performs the sequencing of DNA, and companies working with Ad ...
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is currently enrolling.
The purpose of this study is to evaluate what effects, good or bad, the investigational drug AV-101, comparedt to placebo, has on people with pulmonary arterial hypertension (PAH). In order to measure success for this study it ...
IMPROVE: MedStar Cardiovascular Research Network/IMPact on Revascularization Outcomes of intraVascular ultrasound guided treatment of complex lesions and Economic impact
This study is currently enrolling.
The study will assess whether the use of IVUS improves subjects’ clinical outcomes at 1 year following this PCI procedure. These subjects will be compared to subjects who did not undergo such IVUS imaging guidance during their ...
INCLINE-101: A Phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors
This study is currently enrolling.
The purpose of this study is to test the safety of an investigational (experimental) drug, TAC-001, to see what affects it has on patients with cancer. TAC-001 is considered investigational in this study because it has not been ...
Inhaled Nitric Oxide Treatment of Extremely Preterm Infants with Delayed Pulmonary Vascular Transition to Reduce the Incidence of Broncho-pulmonary Dysplasia
This study is currently enrolling.
This research is being conducted to see if using inhaled nitric oxide (a gas that is delivered along with oxygen) in extremely preterm infants with pulmonary hypertension will decrease the long-term lung problems and improve th ...
INTERMITTENT HYPOXIA AND CAFFEINE IN INFANTS BORN PRETERM
This study is currently enrolling.
You are being asked to allow your baby to be in this research study because your premature baby was given the medication caffeine as treatment for his/her immature breathing in the neonatal intensive care unit (NICU). Particip ...
Isolation of Tumor Cells, Cancer Stem Cells and
Human Neuronal Stem Cells from Human Brain Tumor Tissue for Analysis of Cancer Stem Cell Markers’ Expression in Cellular Differentiation and Self-renewal for Studying the Effectiveness of Cancer Therapy with Subsequent Identification of Exosomal Biomarkers for Early Diagnostic Purposes
Human Neuronal Stem Cells from Human Brain Tumor Tissue for Analysis of Cancer Stem Cell Markers’ Expression in Cellular Differentiation and Self-renewal for Studying the Effectiveness of Cancer Therapy with Subsequent Identification of Exosomal Biomarkers for Early Diagnostic Purposes
This study is currently enrolling.
The purpose of this clinical trial is to collect and study brain tumor samples to help understand why the tumor grows back and to seek new ways to treat it.
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is currently enrolling.
The purposes of this study are to: • Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib. • Determine whether KO-2806 has an antitumor effect (reduces the size of your tumor ...
Lexeo Therapeutics / “A 52-Week, Multicenter, Phase 1 Open-label Study to Evaluate the Safety of LX1001 in Patients with APOE4 Homozygote Alzheimer’s Disease”
This study is currently enrolling.
The study will test LX1001, which is also called AAVrh.10hAPOE2. LX1001 is a new investigational drug that is being developed for treating people like you with AD. It is not approved, by health authorities such as the US Food ...